- Home
- SPRY
as 07-26-2024 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $18.33 | AVG Volume (30 days): | 890.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.55 - $11.90 | Next Earning Date: | 08-08-2024 |
| Revenue: | $10,000 | Revenue Growth: | -98.51% |
| Revenue Growth (this year): | 21456.67% | Revenue Growth (next year): | 841.30% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jul 9 '24 | Sell | $9.62 | 50,000 | $480,840.00 | 1,648,499 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jul 9 '24 | Sell | $9.62 | 50,000 | $480,885.00 | 1,496,494 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jul 9 '24 | Sell | $9.62 | 50,000 | $480,840.00 | 1,648,499 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jul 9 '24 | Sell | $9.62 | 50,000 | $480,885.00 | 1,496,494 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jun 11 '24 | Sell | $9.00 | 2,166 | $19,498.33 | 1,594,328 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jun 11 '24 | Sell | $9.00 | 1,972 | $17,755.69 | 1,746,527 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jun 11 '24 | Sell | $9.15 | 47,834 | $437,461.06 | 1,546,494 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Jun 11 '24 | Sell | $9.14 | 48,028 | $439,201.65 | 1,698,499 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jun 11 '24 | Sell | $9.00 | 2,166 | $19,498.33 | 1,594,328 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jun 11 '24 | Sell | $9.00 | 1,972 | $17,755.69 | 1,746,527 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jun 11 '24 | Sell | $9.15 | 47,834 | $437,461.06 | 1,546,494 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Jun 11 '24 | Sell | $9.14 | 48,028 | $439,201.65 | 1,698,499 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.06 | 44,350 | $401,709.00 | 1,748,499 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.06 | 44,746 | $405,313.74 | 1,597,447 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.04 | 2,766 | $25,005.47 | 1,792,849 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.05 | 2,381 | $21,559.24 | 1,642,193 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.01 | 2,884 | $25,972.73 | 1,795,615 | SEC Form 4 |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | May 14 '24 | Sell | $9.01 | 2,873 | $25,881.13 | 1,644,574 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.01 | 2,873 | $25,881.13 | 1,644,574 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.01 | 2,884 | $25,972.73 | 1,795,615 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.05 | 2,381 | $21,559.24 | 1,642,193 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.04 | 2,766 | $25,005.47 | 1,792,849 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.06 | 44,746 | $405,313.74 | 1,597,447 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 14 '24 | Sell | $9.06 | 44,350 | $401,709.00 | 1,748,499 | SEC Form 4 |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | May 7 '24 | Sell | $9.34 | 50,000 | $467,230.00 | 1,798,499 | SEC Form 4 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
US Growth Companies With Insider Ownership As High As 31%
MT Newswires
a month ago
ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion
GlobeNewswire
a month ago
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
Simply Wall St.
a month ago
US Growth Companies With High Insider Ownership To Watch
Simply Wall St.
a month ago
Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
Simply Wall St.
2 months ago
Top US Growth Companies With High Insider Ownership To Watch In May 2024
GuruFocus.com
2 months ago
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...
Simply Wall St.
3 months ago
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.